Pasithea Therapeutics (KTTA) Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS Nov 9, 2023 07:59AM
Pasithea Therapeutics (KTTA) reports publication showing increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved Aug 1, 2023 08:00AM
Pasithea Therapeutics (KTTA) Acquires AlloMek Therapeutics Oct 12, 2022 08:03AM
Pasithea Therapeutics (KTTA) Acquires Alpha-5 Integrin, LLC Jun 22, 2022 08:04AM